Secukinumab Provides Clinical Benefit for JIA Subtypes Secukinumab Provides Clinical Benefit for JIA Subtypes
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.Medscape Medical News
CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents. PMID: 33034437 [PubMed - as supplied by publisher]
Conclusion: This large study did not support that a high intake of fibre and/or a low intake of meat had a high impact on the risk of late-onset CID. PMID: 33029091 [PubMed - in process]
CONCLUSIONS: In this review, we include a study of the new anti-IL-17 biological agents (secukinumab, ixekizumab, and bromalizumab ) used for moderate-to-severe psoriasis and psoriatic arthritis treatment in clinical practice, as well as pivotal trials with bimekizumab. We study the relationship of these biological agents and the appearance of candidiasis in its various clinical forms. PMID: 33026212 [PubMed - as supplied by publisher]
ConclusionsPD enthesitis was found in the majority of patients with active axSpA and PsA, independent of axial or peripheral affectation. Both MASEI and OMERACT PD definitions were useful in detecting active enthesitis. These findings support the usefulness of a PD US evaluation of entheses in the assessment of axSpA and PsA.Key Points•PD enthesitis is a very common finding in patients with active axSpA and PsA•Both MASEI and OMERACT PD definitions are useful to detect active enthesitis•US enthesitis may reveal information in axSpA and PsA
A group of experts have summarized and made recommendations about recent findings regarding infections that can occur during treatment for rheumatoid arthritis and psoriatic arthritis.Medscape Medical News
AbstractJuvenile idiopathic arthritis (JIA) encompasses several forms of chronic inflammatory arthritis of unknown etiology presenting in children
Abstract Juvenile idiopathic arthritis (JIA) encompasses several forms of chronic inflammatory arthritis of unknown etiology presenting in children
Publication date: Available online 6 October 2020Source: Best Practice &Research Clinical RheumatologyAuthor(s): Sibel Zehra Aydin, Ashish J. Mathew, Sahil Koppikar, Lihi Eder, Mikkel Østergaard
Cyclic adenosine monophosphate (cAMP) acts as a second messenger for intercellular signal transduction. In particular, the cAMP-PKA-CREB pathway is crucial for the regulation of inflammatory genes in immune cells. To target that pathway in immune responses, phosphodiesterase 4 (PDE4) inhibitors that inhibit the conversion of cAMP to AMP were developed.  Apremilast, a PDE4 inhibitor, was approved for the oral treatment of psoriasis and psoriatic arthritis. Additionally, a modest efficacy of apremilast for atopic dermatitis (AD) has been shown. Crisaborole, another PDE4 inhibitor, was approved for the topical treatment...
ConclusionsLack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.